| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000017495 |
| Receipt No. | R000020277 |
| Official scientific title of the study | Establish the suitable strategy of maintenance therapy for rheumatoid arthritis patient with methotrexate and adalimumab |
| Date of disclosure of the study information | 2015/11/26 |
| Last modified on | 2016/11/10 (Ver. 7) |
| Basic information | ||
| Official scientific title of the study | Establish the suitable strategy of maintenance therapy for rheumatoid arthritis patient with methotrexate and adalimumab | |
| Title of the study (Brief title) | Methotraxate and Adalimumab study, to Space and TapEr for Rheumatoid arthritis patients at maintenance period (MASTER study) | |
| Region |
|
|
| Condition | |||
| Condition | rheumatoid arthritis(RA) | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To establish the suitable strategy of the maintenance therapy for RA patient with methotrexate(MTX) and adalimumab(ADA), through investigating the possibility of reducing the dose of the drugs |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | MTX reducing group: last MTX dose
ADA spacing group: last intervals of ADA |
| Key secondary outcomes | at 48 weeks) the rate of maintain of DAS28<2.6
the possibility of MTX reducing and stopping the possibility of ADA spacing and stopping the concentration of MTX-PG the transition of disease activity |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Dose comparison |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | dose maintain group: no change of treatment
|
|
| Interventions/Control_2 | MTX reducing group: reduce 2mg/week of MTX at ever 8 weeks. If remission is maintained at MTX 2mg/week, MTX will be stopped.
|
|
| Interventions/Control_3 | ADA spacing group: space the intervals of ADA for 1week at ever 8 weeks. If remission is maitained at the 6 weeks-intervals of ADA, ADA is stopped. | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) the RA patients comfortable for the 1987 ACR RA classification criteria or 2010 ACR/EULAR RA classification criteria.
2) the patients who are maintaining RA crinical remission(DAS28<2.6) with MTX and 40mg/2weeks of ADA during 6 month. 3) the patients who agree this study after sufficient informed consent. |
|||
| Key exclusion criteria | 1) the patient who are assessed unsuitable. | |||
| Target sample size | 75 | |||
| Research contact person | |
| Name of lead principal investigator | Tsutomu Takeuchi |
| Organization | Keio University School of Medicine, Japan. |
| Division name | Division of Rheumatology, Department of Internal Medicine, |
| Address | 35 Shinanomachi Shinjuku-ku Tokyo Japan |
| TEL | 03-3353-1211 |
| tsutake@keio.jp | |
| Public contact | |
| Name of contact person | Yuko Kaneko |
| Organization | Keio University School of Medicine, Japan. |
| Division name | Division of Rheumatology, Department of Internal Medicine, |
| Address | 35 Shinanomachi Shinjuku-ku Tokyo Japan |
| TEL | 03-3353-1211 |
| Homepage URL | |
| ykaneko@z6.keio.jp | |
| Sponsor | |
| Institute | Keio University School of Medicine, Japan. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Division of Rheumatology, Department of Internal Medicine. |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000020277 |